^
    5d
    Study With [225Ac]Ac-FL-020 in mCRPC Participants (clinicaltrials.gov)
    P1, N=50, Recruiting, Full-Life Technologies GmbH | N=35 --> 50 | Trial primary completion date: Dec 2025 --> Jun 2026
    Enrollment change • Trial primary completion date • First-in-human
    |
    225Ac-FL-020
    5d
    Low-Count Quantitative SPECT for Men Treated With Radium-223 (clinicaltrials.gov)
    P=N/A, N=38, Not yet recruiting, Washington University School of Medicine | Trial completion date: Nov 2027 --> Mar 2028 | Initiation date: Nov 2025 --> Mar 2026 | Trial primary completion date: Aug 2027 --> Dec 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Xofigo (radium Ra-223 dichloride)
    11d
    Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=9, Recruiting, First Affiliated Hospital of Fujian Medical University
    New P1/2 trial
    14d
    ACTION-1: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (clinicaltrials.gov)
    P3, N=288, Recruiting, RayzeBio, Inc. | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101)
    18d
    Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors (clinicaltrials.gov)
    P1, N=48, Recruiting, Orano Med LLC | Trial completion date: Aug 2027 --> May 2032 | Trial primary completion date: Aug 2026 --> Jan 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 expression • HER-2 negative + ER positive
    |
    212Pb-DOTAM-GRPR1
    19d
    Radium-223 in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Xofigo (radium Ra-223 dichloride)
    20d
    Efficacy of Ra-223 in PSMA PET Optimally Selected Patients (clinicaltrials.gov)
    P2, N=2, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting | N=54 --> 2 | Trial completion date: May 2028 --> Mar 2027 | Trial primary completion date: May 2026 --> Jan 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    Xofigo (radium Ra-223 dichloride)
    25d
    Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors (clinicaltrials.gov)
    P1/2, N=138, Recruiting, Molecular Partners AG | Not yet recruiting --> Recruiting | Trial completion date: Sep 2030 --> Sep 2032
    Enrollment open • Trial completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    26d
    A Phase 1 Study of [225Ac]-FPI-1434 Injection (clinicaltrials.gov)
    P1, N=78, Terminated, Fusion Pharmaceuticals Inc. | N=253 --> 78 | Active, not recruiting --> Terminated; A strategic decision was made to discontinue the study and prioritize other programs within the portfolio. The study was not discontinued due to safety issues or adverse events related to FPI-1434, FPE-1547, or FPI-1175.
    Enrollment change • Trial termination • First-in-human
    |
    IGF1 (Insulin-like growth factor 1)
    |
    HER-2 negative
    |
    FPI-1434
    27d
    DORA: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer (clinicaltrials.gov)
    P3, N=732, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    docetaxel • Xofigo (radium Ra-223 dichloride)
    28d
    In-situ ²²³Ra-doped calcium-alginate composite microspheres: a high-LET and immunoactivating platform for α-particle radioembolization in hepatocellular carcinoma. (PubMed, J Nanobiotechnology)
    Transcriptomics reveals activation of DNA-damage response, immunogenic cell death, and antigen-presentation pathways, flow cytometry and immunohistochemistry show increased dendritic-cell maturation and CD8⁺ T-cell infiltration. Collectively, 223Ra/Ca-ALG MS demonstrates hypoxia-tolerant cytotoxicity, immune-activating potential, offering new insights for the development of immune-based TARE strategies in HCC and showing promising prospects for clinical translation.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Xofigo (radium Ra-223 dichloride)
    1m
    AcTFirst: Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC (clinicaltrials.gov)
    P3, N=940, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Sep 2028 --> Feb 2028
    Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • 225Ac-vipivotide tetraxetan (AAA817)